NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
39 trialsNCT06171269 2026-03-04
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
University of Chicago
Phase NA Recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04983095 2026-02-17
METRO
UmeƄ University
Phase NA Recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT06235697 2026-01-13
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07313241 2025-12-31
(RANGER)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07260435 2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3 Recruiting
NCT06861192 2025-11-18
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
Zhongda Hospital
Phase 2/3 Recruiting
NCT06150417 2025-11-12
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT07216248 2025-10-29
OPTIMAS
University of Utah
Phase 2 Recruiting
NCT06244004 2025-10-22
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT07172685 2025-09-15
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT06834321 2025-09-08
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
Zhongda Hospital
Phase 2 Recruiting
NCT05649943 2025-09-03
APPROACH
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase NA Recruiting
NCT06687421 2025-09-03
SPRINTR-REAL
Region VƤsterbotten
Recruiting
NCT07142967 2025-08-27
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
NYU Langone Health
Phase NA Recruiting
NCT06392295 2025-06-15
OCEAN
University of Miami
Phase 2 Recruiting
NCT05790213 2025-06-12
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
University of Chicago
Phase 2 Recruiting
NCT06992232 2025-05-28
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06972511 2025-05-15
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
RenJi Hospital
Phase 2/3 Recruiting
NCT06212583 2025-05-01
KNIGHTS
University of Maryland, Baltimore
Phase 2 Recruiting
NCT06582446 2025-03-11
HypoElect
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT06446401 2025-03-04
Lead4Care
Uppsala University
Recruiting
NCT06818682 2025-02-21
RELAX
Tata Memorial Centre
Phase 2 Recruiting
NCT06772441 2025-01-13
HypoPro
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT06276465 2024-12-20
PEACE8
UNICANCER
Phase 3 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT06709326 2024-11-29
APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer
UmeƄ University
Phase NA Recruiting
NCT05404139 2024-11-25
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT05352178 2024-07-03
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Phase 3 Recruiting
NCT06305832 2024-03-12
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05851547 2024-01-05
DEFINE
Ottawa Hospital Research Institute
Phase 2 Recruiting
NCT05753566 2023-03-06
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting